trending Market Intelligence /marketintelligence/en/news-insights/trending/hf5QO3UYmnmKy5OR9WAEiA2 content esgSubNav
In This List

PharmaMar, Jazz Pharmaceuticals' drug deal receives US antitrust clearance

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


PharmaMar, Jazz Pharmaceuticals' drug deal receives US antitrust clearance

PharmaMar SA and Jazz Pharmaceuticals PLC's exclusive license deal for lung cancer drug Zepsyre received antitrust clearance in the U.S.

Under the agreement's terms, PharmaMar will receive an up-front payment of $200 million and up to $250 million if certain regulatory milestones are achieved.

PharmaMar could also receive up to $550 million in potential commercial milestone payments, as well as royalties from a percentage in the high teens to as much as 30% of future net sales of the drug.

Zepsyre, or lurbinectedin, is under review in the U.S. as a treatment for patients with small cell lung cancer whose disease returned and progressed after prior platinum-based therapy. The medicine holds the U.S. Food and Drug Administration's orphan-drug tag.